ONCO Oncopeptides AB (publ)
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company's PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Oncopeptides (STO: ONCO)
›
Oncopeptides (STO: ONCO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 71 employees.
The shares were at 1.640 SEK on 20 November 2026, down 70.3% over 52 weeks. Its 52-week range is 1.265 SEK to 5.800 SEK: the price is 71.7% below the high and 29.6% above the low.
Its market capitalisation is 707.43M SEK.
Oncopeptides reports return on equity of 423.8%, an operating margin of -178.9% and revenue up 40.7% year over year.
Its debt exceeds its cash by 23.58M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Hold; their mean price target of 2.700 SEK is 64.6% above the current price. The next earnings report is expected on 18 February 2027.